REGENXBIO Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
REGENXBIO Inc. (RGNX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $7.49 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-05
- REGENXBIO Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $7.49M, a 21.81% decline from fiscal 2024.
- REGENXBIO Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $9.58M, a 33.62% decline from fiscal 2023.
- REGENXBIO Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $14.44M, a 14.30% decline from fiscal 2022.
- REGENXBIO Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $16.84M, a 67.45% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $7.49M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $9.58M 10-K · filed 2026-03-05 | $9.62M 10-K · filed 2025-03-13 |
| 2023-12-31 | $14.44M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $16.84M 10-K · filed 2025-03-13 | |
| 2021-12-31 | $10.06M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $7.79M 10-K · filed 2023-02-28 | |
| 2019-12-31 | $11.07M 10-K · filed 2022-03-01 | |
| 2018-12-31 | $7.85M 10-K · filed 2021-03-01 | |
| 2017-12-31 | $6.30M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $7.28M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |